Oppenheimer Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $165
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $160 to $165.
October 06, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer maintains an Outperform rating on Neurocrine Biosciences and raises the price target from $160 to $165, which could positively impact the stock.
The raised price target by Oppenheimer indicates a positive outlook for Neurocrine Biosciences. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100